Phase II Study: Transcatheter Arterial Chemoembolization Therapy In Combination With Sorafenib (TACTICS).

Trial Profile

Phase II Study: Transcatheter Arterial Chemoembolization Therapy In Combination With Sorafenib (TACTICS).

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 05 Jun 2018

At a glance

  • Drugs Sorafenib (Primary) ; Antineoplastics
  • Indications Liver cancer
  • Focus Therapeutic Use
  • Acronyms TACTICS
  • Most Recent Events

    • 05 Jun 2018 Primary endpoint (Progression Free Survival) has been met, as per the results presented at the 54th Annual Meeting of the American Society of Clinical Oncology
    • 05 Jun 2018 Results presented at the 54th Annual Meeting of the American Society of Clinical Oncology
    • 20 Jan 2018 Results presented at the 2018 Gastrointestinal Cancers Symposium
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top